Text Size:AAA

휴먼 Urokinase/PLAU Gene ORF cDNA clone expression plasmid, N-Flag 태그

데이터시트리뷰프로토콜
제품 설명: Active  
발현 숙주: Human Cells  
  • Slide 1
10815-H08H-20
10815-H08H-10
20 µg 
10 µg 
Add to Cart
제품 설명: Active  
발현 숙주: Human Cells  
  • Slide 1
10815-H08H-A-20
10815-H08H-A-10
20 µg 
10 µg 
Add to Cart
발현 숙주: Human Cells  
  • Slide 1
81600-R08H-50
81600-R08H-10
50 µg 
10 µg 
Add to Cart
반응성: Human  
신청: 
    10815-T16-50
    10815-T16-200
    10815-T16-100
    50 µg 
    200 µg 
    100 µg 
    Add to Cart
    반응성: Human  
    신청: 
      10815-MM02-50
      10815-MM02-200
      10815-MM02-100
      10815-MM02-1
      50 µg 
      200 µg 
      100 µg 
      1 mg 
      Add to Cart
      반응성: Human  
      신청: ELISA  
        10815-MM03-50
        10815-MM03-200
        10815-MM03-100
        50 µg 
        200 µg 
        100 µg 
        Add to Cart
        반응성: Human  
        신청: 
          10815-MM05-50
          10815-MM05-200
          10815-MM05-100
          10815-MM05-1
          50 µg 
          200 µg 
          100 µg 
          1 mg 
          Add to Cart

          Urokinase/PLAU ELISA Pair Set

          검출 한계: 15.625 pg/ml
          SEK10815-5
          SEK10815-15
          5 Plates 
          15 Plates 
          Add to Cart

          Urokinase/PLAU cDNA ORF CloneRelated Products

          Related Products

          Featured Reagent Products

          Urokinase/PLAU cdna-clone 연구배경

          Plasminogen activator, urokinase, also known as PLAU and uPA, is a serine protease which converts plasminogen to plasmin, a broad-spectrum protease active on extracellular matrix (ECM) components. It is involved in complement activation, cell migration, wound healing, and generation of localized extracellular proteolysis during tissue remodelling, pro-hormone conversion, carcinogenesis and neoplasia. Like many components of the blood coagulation, fibrinolytic and complement cascades, uPA has a modular structure, including three conserved domains: a growth factor-like domain (GFD, residues 1-49), a kringle domain (residues 50-131), linked by an interdomain linker or "connecting peptide" (CP, residues 132-158) to the serine protease domain (residues 159-411). uPA and its receptor (uPAR) have been implicated in a broad spectrum of pathophysiological processes, including fibrinolysis, proteolysis, inflammation, atherogenesis and plaque destabilization, all of which are involved in the pathogenesis of MI (myocardial infarction). The role of uPA is not only linked to its action as an enzyme. In fact, the mere binding of uPA on the cell surface also brings about two events that broaden the spectrum of its biological functions: (1) a conformational change of the receptor, which, in turn, affects its interaction with other proteins; (2) a signal transduction which modulates the expression of apoptosis-related genes. Besides its applications as a thrombolytic agent and as a prognostic marker for tumors, uPA may provide the basis for other therapies, as the structure of the receptor-binding domain of uPA has become a model for the design of anti-cancer molecules. Because of the causal involvment of uPA in cancer invasion and metastasis, the blockade of uPA interactions and activity with specific inhibitors is of interest for novel strategies in cancer therapy.

          휴먼 Urokinase/PLAU cdna-clone 참고자료
        • Crippa MP. (2007) Urokinase-type plasminogen activator. Int J Biochem Cell Biol. 39(4): 690-4.
        • Kunamneni A, et al. (2008) Urokinase-a very popular cardiovascular agent. Recent Pat Cardiovasc Drug Discov. 3(1): 45-58.
        • Vincenza Carriero M, et al. (2009) Structure, function and antagonists of urokinase-type plasminogen activator. Front Biosci. 14: 3782-94.
        • Xu J, et al. (2010) Association of putative functional variants in the PLAU gene and the PLAUR gene with myocardial infarction. Clin Sci (Lond). 119(8): 353-9.
        • 주의 : 모든 제품은 "연구 목적만을 위한 것이며 진단이나 치료에 사용하도록 의도되지 않았습니다".